Edward Humphries
Director of Discovery Biology Maxion Therapeutics
Seminars
Thursday 24th September 2026
KnotBody® Technology: Engineering Ion Channel–Modulating Antibodies via Knottin Integration into Antibody Loops
9:00 am
- Overview of the KnotBody Platform: A novel approach enabling potent, selective, and durable modulation of ion channels
- Lead Optimisation Highlights: Progress towards optimised KnotBody candidates targeting autoimmune diseases, demonstrating enhanced efficacy and developability
- Platform Versatility: Evidence of broad applicability across diverse target classes, underscoring the flexibility of the KnotBody platform
Thursday 24th September 2026
Panel: Comparing Modality Selection Decisions to Match Biology & Indication Requirements
12:00 pm
- Examining how biology, delivery constraints & safety risk shaped final modality choices
- Weighing durability, tissue access, reversibility & tolerability across competing strategies
- Identifying modality decision principles that remain consistent across CNS & peripheral programs
